ImmunityBio, Inc.

IBRXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1326110

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$622.0K	$240.0K	—	—	—
Cost of Goods and Services Sold	$0.00	$0.00	—	—	—
Research and Development Expense	—	$248.1M	$41.1M	$139.5M	$112.0M
Selling, General and Administrative Expense	—	$102.7M	$45.3M	$71.3M	$46.5M
Operating Expenses	—	$351.5M	$331.2M	$221.5M	$158.5M
Operating Income (Loss)	-$362.3M	-$351.3M	-$86.3M	-$220.9M	-$156.3M
Interest Expense	$128.8M	$63.5M	$14.8M	$9.1M	$5.9M
Nonoperating Income (Expense)

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$382.9M	$504.5M	$362.4M	$468.9M	$221.4M
Assets, Current	$184.6M	$294.1M	$140.6M	$334.3M	$111.7M
Cash and Cash Equivalents, at Carrying Value	$265.5M	$104.6M	$181.1M	$34.9M	$75.8M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.4M	$0.00	—	—	—
Inventory, Net	$8.3M	$0.00	—	—	—
Liabilities	$871.1M	$1.1B	$812.2M	$712.8M	$339.9M
Liabilities, Current	$54.9M	$58.3M	$500.9M	$369.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$366.8M	-$337.5M	-$274.4M	-$171.7M	-$152.1M
Net Cash Provided by (Used in) Investing Activities	-$30.5M	$27.3M	-$84.9M	-$19.8M	$18.6M
Net Cash Provided by (Used in) Financing Activities	$558.3M	$233.6M	$505.4M	$150.7M	$114.3M
Payments to Acquire Property, Plant, and Equipment	$30.6M	$78.2M	$33.6M	$1.7M	$4.3M
Payments for Repurchase of Common Stock	—	—	—	—	$2.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)